CO2019013317A2 - Oligonucleótidos antisentido para la modulación de la expresión de htra1 - Google Patents
Oligonucleótidos antisentido para la modulación de la expresión de htra1Info
- Publication number
- CO2019013317A2 CO2019013317A2 CONC2019/0013317A CO2019013317A CO2019013317A2 CO 2019013317 A2 CO2019013317 A2 CO 2019013317A2 CO 2019013317 A CO2019013317 A CO 2019013317A CO 2019013317 A2 CO2019013317 A2 CO 2019013317A2
- Authority
- CO
- Colombia
- Prior art keywords
- modulation
- antisense oligonucleotides
- htra1
- htra1 expression
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21108—HtrA2 peptidase (3.4.21.108)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a oligonucleótidos (oligómeros) antisentido que son complementarios a HTRA1, que conducen a la modulación de la expresión de HTRA1. La modulación de la expresión de HTRA1 resulta beneficiosa para un abanico de trastornos médicos, tales como la degeneración macular, por ejemplo, la degeneración macular asociada a la edad.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17173964 | 2017-06-01 | ||
EP17209535 | 2017-12-21 | ||
EP17209407 | 2017-12-21 | ||
PCT/EP2018/064221 WO2018220034A1 (en) | 2017-06-01 | 2018-05-30 | Antisense oligonucleotides for modulating htra1 expression |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019013317A2 true CO2019013317A2 (es) | 2020-01-17 |
Family
ID=62245334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0013317A CO2019013317A2 (es) | 2017-06-01 | 2019-11-27 | Oligonucleótidos antisentido para la modulación de la expresión de htra1 |
Country Status (19)
Country | Link |
---|---|
US (3) | US20190055564A1 (es) |
EP (1) | EP3630976A1 (es) |
JP (1) | JP7169995B2 (es) |
KR (1) | KR20200015608A (es) |
CN (1) | CN110691849A (es) |
AU (1) | AU2018277219A1 (es) |
BR (1) | BR112019025290A2 (es) |
CA (1) | CA3062590A1 (es) |
CL (1) | CL2019003337A1 (es) |
CO (1) | CO2019013317A2 (es) |
CR (1) | CR20190543A (es) |
IL (1) | IL271039A (es) |
MA (1) | MA49278A (es) |
MX (1) | MX2019014187A (es) |
PE (1) | PE20191845A1 (es) |
PH (1) | PH12019502636A1 (es) |
RU (1) | RU2019143004A (es) |
TW (1) | TW201907008A (es) |
WO (1) | WO2018220034A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20180606A (es) | 2016-07-01 | 2019-02-14 | Hoffmann La Roche | Oligonucleótidos antisentido para modular la expresión de htra1 |
EP3752612A4 (en) | 2018-02-12 | 2021-11-10 | Ionis Pharmaceuticals, Inc. | MODIFIED COMPOUNDS AND USES THEREOF |
KR20230095097A (ko) * | 2020-10-30 | 2023-06-28 | 히데아키 하라 | 눈 조직 섬유화의 저해에 사용하기 위한 gdf15 조절 물질 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
NZ503765A (en) | 1997-09-12 | 2002-04-26 | Exiqon As | Bi-cyclic and tri-cyclic nucleotide analogues |
AU5290499A (en) * | 1998-08-03 | 2000-02-28 | Novartis Ag | Human htra serine protease |
ID30093A (id) | 1999-02-12 | 2001-11-01 | Sankyo Co | Analog-analog nukleosida dan oligonukleotida baru |
JP2002543214A (ja) | 1999-05-04 | 2002-12-17 | エクシコン エ/エス | L−リボ−lna類縁体 |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
DK2752488T3 (da) | 2002-11-18 | 2020-04-20 | Roche Innovation Ct Copenhagen As | Antisense-design |
US20090221671A1 (en) * | 2005-05-24 | 2009-09-03 | Sanjay Pandey | Modulation of lmw-ptpase expression |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
CA2640171C (en) | 2006-01-27 | 2014-10-28 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
WO2007134181A2 (en) | 2006-05-11 | 2007-11-22 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
EP2044223B1 (en) * | 2006-07-26 | 2012-06-27 | Yale University, Inc. | Diagnosis and treatment of age related macular degeneration |
WO2008067040A2 (en) * | 2006-10-06 | 2008-06-05 | University Of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
TW200911290A (en) * | 2007-07-02 | 2009-03-16 | Alcon Res Ltd | RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration |
CA2692579C (en) | 2007-07-05 | 2016-05-03 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
CA2866649A1 (en) * | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Rca locus analysis to assess susceptibility to amd and mpgnii |
WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
DK2356129T3 (da) | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
WO2011017521A2 (en) | 2009-08-06 | 2011-02-10 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
FR2965278B1 (fr) * | 2010-09-23 | 2014-10-10 | Univ Caen Basse Normandie | Procede d'obtention in vitro ou ex vivo de chondrocytes et leurs utilisations |
WO2013036868A1 (en) | 2011-09-07 | 2013-03-14 | Marina Biotech Inc. | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers |
US9221864B2 (en) | 2012-04-09 | 2015-12-29 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
JP2016522674A (ja) * | 2012-05-16 | 2016-08-04 | ラナ セラピューティクス インコーポレイテッド | 遺伝子発現を調節するための組成物及び方法 |
PL2920304T3 (pl) | 2012-11-15 | 2019-07-31 | Roche Innovation Center Copenhagen A/S | Koniugaty oligonukleotydowe |
WO2018087200A1 (en) * | 2016-11-11 | 2018-05-17 | Roche Innovation Center Copenhagen A/S | Therapeutic oligonucleotides capture and detection |
-
2018
- 2018-05-29 US US15/991,326 patent/US20190055564A1/en not_active Abandoned
- 2018-05-30 CR CR20190543A patent/CR20190543A/es unknown
- 2018-05-30 MX MX2019014187A patent/MX2019014187A/es unknown
- 2018-05-30 PE PE2019002473A patent/PE20191845A1/es unknown
- 2018-05-30 BR BR112019025290-8A patent/BR112019025290A2/pt not_active Application Discontinuation
- 2018-05-30 EP EP18727310.7A patent/EP3630976A1/en active Pending
- 2018-05-30 WO PCT/EP2018/064221 patent/WO2018220034A1/en active Application Filing
- 2018-05-30 CA CA3062590A patent/CA3062590A1/en not_active Abandoned
- 2018-05-30 RU RU2019143004A patent/RU2019143004A/ru unknown
- 2018-05-30 JP JP2019566236A patent/JP7169995B2/ja active Active
- 2018-05-30 MA MA049278A patent/MA49278A/fr unknown
- 2018-05-30 CN CN201880036053.5A patent/CN110691849A/zh active Pending
- 2018-05-30 KR KR1020197038723A patent/KR20200015608A/ko unknown
- 2018-05-30 AU AU2018277219A patent/AU2018277219A1/en not_active Abandoned
- 2018-05-31 TW TW107118609A patent/TW201907008A/zh unknown
-
2019
- 2019-10-28 US US16/665,317 patent/US20200157546A1/en not_active Abandoned
- 2019-11-20 CL CL2019003337A patent/CL2019003337A1/es unknown
- 2019-11-22 PH PH12019502636A patent/PH12019502636A1/en unknown
- 2019-11-27 CO CONC2019/0013317A patent/CO2019013317A2/es unknown
- 2019-11-28 IL IL271039A patent/IL271039A/en unknown
-
2021
- 2021-08-17 US US17/404,989 patent/US20220042022A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20200015608A (ko) | 2020-02-12 |
CL2019003337A1 (es) | 2020-05-15 |
IL271039A (en) | 2020-01-30 |
CR20190543A (es) | 2020-02-10 |
AU2018277219A1 (en) | 2019-12-19 |
MX2019014187A (es) | 2020-01-27 |
TW201907008A (zh) | 2019-02-16 |
US20200157546A1 (en) | 2020-05-21 |
CA3062590A1 (en) | 2018-12-06 |
MA49278A (fr) | 2020-04-08 |
CN110691849A (zh) | 2020-01-14 |
JP2020521491A (ja) | 2020-07-27 |
PE20191845A1 (es) | 2019-12-31 |
BR112019025290A2 (pt) | 2020-06-23 |
US20190055564A1 (en) | 2019-02-21 |
EP3630976A1 (en) | 2020-04-08 |
WO2018220034A1 (en) | 2018-12-06 |
PH12019502636A1 (en) | 2020-06-08 |
JP7169995B2 (ja) | 2022-11-11 |
RU2019143004A (ru) | 2021-07-09 |
US20220042022A1 (en) | 2022-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018013240A2 (es) | Oligonucleótidos antisentido para modular la expresión de htra1 | |
BR112017017396A2 (pt) | derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos | |
BR112017012272A2 (pt) | derivados de 2-anilinopirimidina como moduladores de egfr | |
BR112016014020A8 (pt) | moduladores de tetra-hidropiridopirazinas de gpr6. | |
CO2019013317A2 (es) | Oligonucleótidos antisentido para la modulación de la expresión de htra1 | |
DOP2017000120A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
BR122020024446B8 (pt) | Compostos para modulação da expressão do receptor do hormônio de crescimento | |
BR112016029994A2 (pt) | métodos de preparação de análogos de nucleotídeo substituídos | |
CR20170247A (es) | 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
CL2020000085A1 (es) | Moduladores de nlrp3. | |
BR112017007014A2 (pt) | derivados de benzotiofenila substituídos como agonistas do gpr40 para o tratamento de diabetes tipo ii | |
CO2021014008A2 (es) | Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento | |
UY36209A (es) | Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen | |
ECSP16074207A (es) | Pirazinas moduladoras de gpr6 | |
BR112019005886A2 (pt) | tratamento com água de material lipídico | |
DOP2017000196A (es) | Derivados de tetrahidropiranil benzamida | |
AR112908A1 (es) | Oligonucleótidos antisentido para modular la expresión de htra1 | |
BR112017014235A2 (pt) | composição de grupo para a produção de um produto refratário, processo para a produção de um produto refratário, produto refratário e aplicação de um produto refratário. |